about
Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.TPL2 kinase regulates the inflammatory milieu of the myeloma nicheNegative regulation of the tumor suppressor p53 gene by microRNAs.Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin OncologyVcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.Microscale functional cytomics for studying hematologic cancersTumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple MyelomaBortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.Performance of a hybrid central venous catheter utilized for both peripheral blood stem cell harvest and transplant support of patients undergoing autologous peripheral blood stem cell transplantation.Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.Registry results and high-dose therapy.Examiner dependence on physical diagnostic tests for the detection of splenomegaly: a prospective study with multiple observers.Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.Acute chemical meningitis after metrizamide-lumbar myelographyTreatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review
P50
Q27691802-CC98F6A7-12F6-46A4-89CE-E399AF106153Q33418705-EF460FC1-31CA-4CAF-A216-40C01D6712CAQ33714724-0B3D4DED-5EE7-4A67-AAA5-2D78B1FFB38AQ34142778-5C8C1AB5-DECE-43CD-B169-CFEDAC593938Q34245549-EC3D498B-61C5-41D6-B0CB-6589E2978C14Q35285011-2A69D022-AF70-4D87-A2BB-202AEAEB8706Q35849287-A0BECC07-0BC3-4832-BAE3-9E6126EDEF99Q35925252-5B020280-F59F-4DB0-9216-48D329D28484Q36984165-7882ED40-B99A-4F9D-8648-BFBCE77C4F6BQ37222119-52475A8F-AEFB-4A16-BB96-0F1115A58FCCQ40392114-384F81A5-0CBC-4110-B3A1-3FECCC426FDEQ40454635-96E631B4-9889-4254-9423-FC63967299E8Q40574808-81E5AD7C-8419-455C-9956-FD8790B7FAD4Q40611734-5FB05ADE-FF78-44FC-9C8F-AF784A765AF7Q41839288-5C7ADC91-C920-469E-8B0E-E5DCEAD7BB6CQ45111044-73591BE0-E336-4604-B7BE-B81F76C4B1BCQ45190892-DAC636A7-1A7C-4194-9371-A8CEF060CC3BQ46052030-65C873ED-84E7-4B62-9C7A-26F6FE0F4B3BQ53867466-096047DC-0292-4981-BDDF-9F7C160D2D0FQ71719253-13B95088-6205-4D2D-A96F-96AF4D5C22A0Q77160436-D6E92EB1-EC15-4C27-9C57-38CCCF4601C3
P50
description
researcher
@en
name
N S Callandar
@en
N S Callandar
@nl
type
label
N S Callandar
@en
N S Callandar
@nl
prefLabel
N S Callandar
@en
N S Callandar
@nl
P108
P106
P108
P31
P496
0000-0002-6975-1086